Roche and Nurix strike $2.3bn BTK degrader deal for bexobrutideg
Roche has agreed an exclusive global collaboration with Nurix Therapeutics to co-develop and co-commercialise bexobrutideg (NX-5948), an investigational oral BTK degrader, in a deal that could be worth up to USD 2.3 billion in total. Nurix receives a USD 700 million upfront cash payment, with the remainder contingent on development, regulatory and commercial milestones. The transaction is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino antitrust clearance.
The two companies will share development costs — Roche taking 60%, Nurix 40% — and split US profits and losses equally, co-commercialising across all indications domestically. Outside the United States, Roche assumes sole commercialisation responsibility, with Nurix receiving royalties in the low- to high-teens percentage range.
The science case for degradation over inhibition
Bexobrutideg takes a mechanistically distinct approach from the current generation of BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib. Rather than occupying the kinase active site, it harnesses the cell's ubiquitin-proteasome system to eliminate the BTK protein entirely, removing both its kinase activity and its scaffolding function. The company argues this dual elimination addresses the acquired resistance mutations — most notably BTK C481S — that ultimately cause disease progression in a substantial proportion of CLL patients on standard-of-care inhibitors.
The candidate is also brain-penetrant, which underpins its potential in neurological indications. Roche and Nurix plan to initiate a Phase 3 trial in second-line CLL in summer 2026, with additional development paths in chronic spontaneous urticaria (CSU) and multiple sclerosis (MS) also in scope.
Arthur Sands, president and chief executive of Nurix, said the partnership would allow the company to "rapidly expand our Phase 3 programme enhanced by Roche's global reach" and to explore combination regimens drawing on Roche's existing portfolio of B-cell malignancy drugs — a reference to assets including venetoclax, which Roche markets through its Genentech subsidiary.
Market context and competitive dynamics
The BTK inhibitor and degrader market is sizeable and growing. The combined non-Hodgkin lymphoma and CLL segment is projected by Clarivate to reach USD 41 billion by 2031, with BTK-targeting agents forecast to represent approximately USD 19 billion of that total. The CLL slice alone is expected to expand from roughly USD 12 billion in 2024 to USD 16 billion by 2035, according to DRG and Datamonitor Healthcare data cited in the release.
The targeted protein degradation field has attracted considerable pharma interest in recent years, with multiple large-cap companies, including AbbVie and Merck, building or acquiring degrader capabilities. Bexobrutideg sits within the PROTAC and molecular-glue degrader wave, though Nurix uses a proprietary DELigase platform to identify its compounds. The Roche deal is one of the largest upfront payments seen in the degrader space to date, signalling confidence in the differentiation thesis — though the "best-in-class" framing is the company's own characterisation and will require head-to-head or cross-trial comparison data to substantiate.
For Roche, the collaboration fills a gap in its haematology pipeline at a time when the company is navigating biosimilar erosion of its older oncology franchise and rebuilding around novel mechanisms. The cross-therapeutic angle — a single candidate with potential utility in haematology, immunology and neurology — also fits a broader Roche strategy of maximising platform value across disease areas. Near-term focus will fall on Phase 3 initiation in CLL, with immunology and neurology readouts further out on the development timeline.